Skip to content

Cagrilintide

Cagrilintide (CAS 1415456-99-3) is a long-acting amylin analog engineered for metabolic research, with a molecular weight of approximately 4,100.7 Da and molecular formula C₁₈₂H₂₉₃N₄₇O₅₅. Designed as a stable amylin receptor agonist with extended pharmacokinetic properties, cagrilintide mimics the physiological actions of endogenous amylin — a 37-amino acid peptide hormone co-secreted with insulin from pancreatic β-cells. Its engineered structure enables sustained receptor engagement for investigating amylin-mediated metabolic regulation.

Technical Specifications

Property Value
CAS Number 1415456-99-3
Molecular Formula C₁₈₂H₂₉₃N₄₇O₅₅
Molecular Weight ~4,100.7 Da
Purity ≥99% (HPLC-verified)
Appearance Lyophilized white powder
Solubility Soluble in aqueous buffers (pH 7.0–8.0)
Storage -20°C (lyophilized), 2–8°C (reconstituted)

Mechanism of Action

Cagrilintide functions as an agonist at the amylin receptor (AMY), a heterodimeric receptor complex composed of the calcitonin receptor (CTR) and receptor activity-modifying proteins (RAMP1 or RAMP3). Upon receptor binding, amylin signaling activates intracellular cAMP and calcium-dependent pathways in the area postrema and nucleus tractus solitarius of the brainstem, reducing gastric emptying rate and promoting postprandial satiety. Amylin receptor activation also suppresses postprandial glucagon secretion from pancreatic α-cells and modulates vagal afferent signaling to the hypothalamus. Cagrilintide's structural modifications — incorporating strategic amino acid substitutions to the native amylin sequence — confer resistance to proteolytic degradation while maintaining high receptor affinity. When studied in combination with GLP-1 receptor agonists, cagrilintide demonstrates complementary anorectic and glucoregulatory effects through parallel receptor pathways.

Research Applications

  • Primary: Amylin receptor pharmacology — metabolic regulation, gastric emptying, satiety signaling
  • Secondary: Obesity intervention models, combination incretin/amylin receptor research, postprandial glucose control
  • Model Systems: In vitro (recombinant AMY receptor-expressing cell lines), in vivo rodent models (diet-induced obesity, streptozotocin-treated rats)

Quality Control & Analytical Methods

  • HPLC: ≥99% purity verification at 214/220 nm (C18 reversed-phase column)
  • Mass Spectrometry: ESI-MS for molecular weight confirmation (~4,100.7 ±1.0 Da)
  • Peptide Content: Amino acid analysis (AAA) for net peptide content determination
  • Endotoxin: <1 EU/mg (LAL assay)
  • TFA Content: <1% (ion chromatography)

Stability & Storage

Condition Stability
-20°C (lyophilized) 24 months
4°C (lyophilized) 6 months
25°C (lyophilized) 1 month
Reconstituted (4°C) 7 days
Reconstituted (-20°C) 30 days

Key Research References

  • Enebo et al. (2021) — Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of cagrilintide and semaglutide. Lancet Diabetes Endocrinol. PMID: 34089568
  • Hay et al. (2015) — Amylin: pharmacology, physiology, and clinical potential. Pharmacol Rev. PMID: 26071095
  • Bower et al. (2022) — The amylin receptor: an emerging target for metabolic disease. Trends Endocrinol Metab. PMID: 34728120

Source & Purchase

For researchers requiring research-grade CAGRILINTIDE with full analytical documentation including HPLC, LC-MS, and Certificate of Analysis, visit the HK Peptides product page for specifications, bulk pricing, and ordering.

View CAGRILINTIDE Product →

FAQ

Q: What purity level is standard for Cagrilintide? A: HK Peptides supplies Cagrilintide at ≥99% purity by HPLC with full COA documentation.

Q: How should Cagrilintide be stored for research use? A: Lyophilized Cagrilintide should be stored at -20°C. Reconstituted solutions at 4°C for short-term use; aliquot and freeze at -20°C for extended storage.